Matrix Metalloproteinase (MMP) in Heart Failure

This study has been completed.

Sponsored by:	Tottori University Hospital
Information provided by:	Tottori University Hospital
ClinicalTrials.gov Identifier:	NCT00663494

Purpose

The purpose of this study is to evaluate the production of MMP in failing hearts.

Condition
Chronic Stable Heart Failure

MedlinePlus related topics: Heart Failure

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case Control, Prospective
Official Title:	MMP is Produced in Failing Hearts

Further study details as provided by Tottori University Hospital:

Primary Outcome Measures:

MMPs level of coronary sinus

Estimated Enrollment:	22
Study Start Date:	February 2003
Study Completion Date:	July 2006

Detailed Description:

Myocardial fibrosis is observed in failing hearts and pararell to the progression of chronic heart failure (CHF) and myocardial remodeling. Matrix metalloproteinases (MMPs) are considered markers of fibrosis. Recently, circulating MMPs can be measured and are elevated in patients with CHF. However, MMPs it is still unclear whether MMPs are produced in failing hearts. Thus, the purpose of this study is to evaluate the production of MMP in failing hearts.

Eligibility

Genders Eligible for Study:

Both

Study Population

chronic heart failure

Criteria

Inclusion Criteria:

chronic stable heart failure

Contacts and Locations

No Contacts or Locations Provided

More Information

Responsible Party:	Tottori University Hospital ( Kazuhide Ogino )
Study ID Numbers:	#244
Study First Received:	April 18, 2008
Last Updated:	April 18, 2008
ClinicalTrials.gov Identifier:	NCT00663494
Health Authority:	Japan: Ministry of Health, Labor and Welfare

Keywords provided by Tottori University Hospital:

heart failure
MMP
coronary sinus

Study placed in the following topic categories:

Heart Failure
Heart Diseases

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009